Speaker illustration

Doctor Roger J Hajjar

Massachusetts General Brigham - Harvard Medical School, Boston (United States of America)

Member of:

European Society of Cardiology
Heart Failure Association

NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure

Event: Heart Failure 2025

Topic: Treatment

Session: Late-breaking clinical trials in chronic heart failure

Thumbnail

Gene therapy for heart failure

Event: Heart Failure 2018

Topic: Signal Transduction, Mechanotransduction

Session: Positive inotropy - Still an approach we should go for?

Thumbnail

Gene therapy to target calcium cycling in heart failure.

Event: ESC Congress 2017

Topic: Ion channels and electrophysiology

Session: Keep calcium signalling under control to prevent heart failure

Thumbnail

Genome engineering of iPS-derived cardiomyocytes.

Event: ESC Congress 2017

Topic: Genetics and gene therapy

Session: Should we modify the genome to cure cardiovascular disease?

Thumbnail

Role of calcium signalling in diastolic dysfunction

Event: ESC Congress 2016

Topic: Echo-ventricular function

Session: Diastology: from cellular signalling to advanced imaging techniques

Thumbnail